Abstract
Novel nonpeptide angiotensin receptor antagonists are claimed. They are potentially useful for the treatment of a variety of disorders associated with excessive or unregulated angiotensin II (AII) activity such as hypertension, congestive heart failure, cognitive disorders, renal insufficiency associated with diabetic or hypertensive nephrotherapy, glaucoma, kidney damage due to non-steroidal anti-inflammatory agents, and restenosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
